Last reviewed · How we verify
Flublok Quadrivalent
At a glance
| Generic name | Flublok Quadrivalent |
|---|---|
| Sponsor | Fatimah Dawood |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. (PHASE3)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (PHASE1, PHASE2)
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flublok Quadrivalent CI brief — competitive landscape report
- Flublok Quadrivalent updates RSS · CI watch RSS
- Fatimah Dawood portfolio CI